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Abstract
Background: Cystic fibrosis (CF) patients would benefit from a safe and effective tool to detect early-stage, regional lung
disease to allow for early intervention. Magnetic Resonance Imaging (MRI) is a safe, non-invasive procedure capable of
providing quantitative assessments of disease without ionizing radiation. We developed a rapid normalized T1 MRI
technique to detect regional lung disease in early-stage CF patients.
Materials and Methods: Conventional multislice, pulmonary T1 relaxation time maps were obtained for 10 adult CF patients
with normal spirometry and 5 healthy non-CF control subjects using a rapid Look-Locker MRI acquisition (5 seconds/
imaging slice). Each lung absolute T1 map was separated into six regions of interest (ROI) by manually selecting upper,
central, and lower lung regions in the left and right lungs. In order to reduce the effects of subject-to-subject variation,
normalized T1 maps were calculated by dividing each pixel in the absolute T1 maps by the mean T1 time in the central lung
region. The primary outcome was the differences in mean normalized T1 values in the upper lung regions between CF
patients with normal spirometry and healthy volunteers.
Results: Normalized T1 (nT1) maps showed visibly reduced subject-to-subject variation in comparison to conventional
absolute T1 maps for healthy volunteers. An ROI analysis showed that the variation in the nT1 values in all regions was#2%
of the mean. The primary outcome, the mean (SD) of the normalized T1 values in the upper right lung regions, was
significantly lower in the CF subjects [.914 (.037)] compared to the upper right lung regions of the healthy subjects [.983
(.003)] [difference of .069 (95% confidence interval .0322.105); p = .001). Similar results were seen in the upper left lung
region.
Conclusion: Rapid normalized T1 MRI relaxometry obtained in 5 seconds/imaging slice may be used to detect regional
early-stage lung disease in CF patients.
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Introduction
Cystic Fibrosis (CF) is the most common life-shortening
autosomal recessive disorder in persons of European ancestry[1].
The leading cause of morbidity and mortality in CF patients is
progressive respiratory disease. When Dorothy Andersen provided
the first comprehensive description of CF in 1938, survival was
often measured in days and months[2]. Current expected survival
is now 37 years of age[3]. This dramatic improvement in survival
has largely occurred due to interventions improving nutrition and
treating the airway obstruction, infection, and inflammation in
patients with already established CF lung disease[4]. The next
logical step to further increasing life expectancy for CF patients is
to safely detect and treat CF lung disease at early-stages before
irreversible lung damage has occurred[5]. In young children,
early-stage CF lung disease can be characterized by significant
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airway inflammation, infection, and/or obstruction despite no
overt clinical symptoms[6–9]. Adolescent and adult CF patients
with early-stage lung disease are now more common as evidenced
by 50% of CF patients in the United States aged $18 years having
a forced expiratory volume in one second (FEV1) value greater
than 80% of predicted for a healthy population[3]. Clinical tools
such as spirometry, bronchoscopy, and chest imaging are typically
used to detect CF lung disease. Unfortunately, these assessments
are 1) insensitive to detect early-stage, regional lung disease, 2)
invasive, and/or 3) expose patients to potentially injurious ionizing
radiation. Therefore a major barrier to improved care for early-
stage CF patients is the lack of a safe, non-invasive, and effective
test for assessing early, regional lung disease[7].
Magnetic Resonance Imaging (MRI) is a safe, non-invasive
procedure capable of providing quantitative assessments of disease
without ionizing radiation. MRI techniques, such as hyperpolar-
ized gas imaging as well as proton-based oxygen-enhanced MRI
and arterial spin labeling, have been shown to detect CF lung
disease[10–15]. However, these methods are not widely available,
require specialized expensive materials, and/or require multiple
lengthy acquisitions resulting in significant respiratory motion
artifacts. In addition, no prior studies conducted were focused on
detection of early-stage lung disease in CF patients, a timepoint
when therapeutics and interventions may be most effective. These
practical limitations have prevented clinical adoption of these MRI
techniques despite promising initial clinical results.
To address this clinical need, we have developed a normalized
T1 MRI (nT1-MRI) technique to quantitatively assess regional CF
lung disease. The nT1-MRI technique builds upon previous
oxygen-enhanced MRI developments which measure the longitu-
dinal magnetic relaxation time (absolute T1) of lung regions under
respired air and oxygen in succession[13]. The T1 magnetic
relaxation time generally measures the relative time required for a
substance to become magnetized after being placed in a magnetic
field. The absolute T1 magnetic relaxation time is a tissue-specific
property with adipose tissue and other soft tissue organs having
relatively short T1 times (,1000 ms at 1.5T), while blood and
other body fluids having a longer T1 relaxation time (.1000 ms at
1.5T). The new nT1-MRI technique described herein requires
only one T1 assessment under respired ambient room air and
therefore offers the following advantages: 1) rapid image
acquisition (5 seconds/imaging slice), 2) minimization of respira-
tory motion artifacts and elimination of tedious image co-
registration, 3) potential to be implemented on virtually any
conventional MRI scanner, and 4) no exogenous contrast agents
or specialized breathing apparatus are required. Furthermore,
since CF lung disease is known to be regional, first appearing in
the upper lung regions before the lower regions, and the central
lung regions in CF patients with early-stage lung disease typically
have no or minimal lung disease[16], we hypothesized that using a
region of interest (ROI) analysis, with the ‘‘disease-free’’ central
regions acting as a control, the nT1-MRI technique would be
sensitive enough to detect early-stage CF lung disease that first
appears in the upper lung regions. As such, nT1-MRI may be an
ideal diagnostic test for assessing early-stage CF lung disease.
Importantly, the normalized T1 technique also improves upon
previous studies by reducing subject-to-subject anatomic variation
observed in conventional T1 relaxometry assessments and thereby
allowing reliable delineation of lung lesions among CF patients.
To determine if the normalized T1 technique may be a
potential tool to evaluate regional lung disease in CF patients, we
performed an initial cross-sectional study to compare adult CF
patients with early-stage lung disease to healthy volunteers. We
hypothesized that the nT1-MRI technique would provide a safe
and effective tool to detect regional lung abnormalities in early-
stage CF patients with ‘‘normal’’ spirometry results.
Materials and Methods
Ethics Statement
All patients provided written informed consent and the
institutional review board of University Hospitals Case Medical
Center approved the study.
Human Subjects and Spirometry
Adult cystic fibrosis patients were recruited for this initial cross-
sectional MRI study from the patient population of the Cleveland
Adult Cystic Fibrosis Center at Rainbow Babies and Children’s
Hospital between June 2012 and February 2013. All MRI scans
and spirometry were obtained according to Institutional Review
Board approved protocols. Patients were included in the study if
they met diagnostic criteria for cystic fibrosis[17] and were aged
$18 years. Patients were excluded if they had a contraindication
to MRI or the patient’s respiratory status was not at baseline (i.e.
they were experiencing a pulmonary exacerbation). Five healthy
adult non-CF subjects with no history of respiratory disease were
recruited as controls. Spirometry was obtained for each CF patient
and healthy volunteer immediately prior to or immediately
following the MRI scan. All spirometry was performed in
accordance with American Thoracic Society guidelines and forced
expiratory volume in one second (FEV1) percent predicted values
were calculated using reference equations[18]. For the purposes of
this study, we defined early-stage CF lung disease as a CF subject
with an FEV1$70% predicted.
MRI Acquisition
Each subject was scanned in a supine position with a Siemens
Espree 1.5T MRI scanner (70 cm bore). Spine array (posterior)
and body array (anterior) receiver coils were positioned over each
subject’s chest to maximize image uniformity. Following initial
localizer scans, coronal proton density-weighted HASTE images
(Half-Fourier Acquisition Single-shot Turbo spin Echo, respirato-
ry-triggered, TR/TE=1000/24 ms, slice thickness = 15 mm, 10
slices, FOV=400 mm6400 mm, partial Fourier factor 5/8, 1
average) were obtained to position the coronal slices for the T1
relaxation assessments. A rapid Look-Locker acquisition was then
used to generate T1 recovery data (TR/TE=1.8 ms/0.84 ms,
FOV=4006400 mm, resolution = 646128, flip angle = 8u, slice
thickness = 15 mm, 40 images following the initial inversion) as
described previously[19]. The imaging data were zero-padded to
1286128 isotropic resolution prior to reconstruction and absolute
T1 mapping. This acquisition was applied with a 5-second
breathhold to obtain T1 recovery data for one imaging slice at a
time. The Look-Locker acquisition was then repeated for 8–10
imaging slices to obtain complete lung coverage.
Absolute and Normalized T1 Calculations and Region of
Interest (ROI) Analysis
Absolute T1 relaxation time maps were calculated online
according to established methods[19]. The absolute T1 maps and
all MRI images were then exported and processed offline in
Matlab (The Mathworks, Natick, MA). A region-of-interest (ROI)
analysis was performed to calculate the normalized T1 maps. Six
total ROIs were manually selected for each imaging slice as shown
in Figure 1. The ROIs were selected with pulmonary and
radiological expertise provided by Drs. Dasenbrook and Flask,
similar to other previously published CF imaging studies [16,20].
The central ROI was chosen as the region with the largest
MRI and Cystic Fibrosis
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pulmonary blood vessels identified by the highest absolute T1
values (dark red regions in Fig. 1a). These regions generally
extended from the hilum of the trachea to the base of the lung.
The upper and lower ROIs of each lung were chosen from the
remaining regions to identify lung disease in the lower and upper
halves of each lung. The mean absolute T1 value for the central
ROI was then used to calculate the normalized T1 (nT1) value for
each image pixel according to Equation 1 below:
nT1(x,y:z)~T1(x,y:z)=T1central,mean ð1Þ
where nT1(x,y.z) is the normalized T1 value for an individual
pixel at spatial location x,y, and z; T1(x,y.z) is the absolute T1
relaxation time (in milliseconds) for an individual pixel at spatial
location x,y, and z, and T1central,mean is the mean absolute T1
relaxation time in the central lung region. The central lung region
was chosen as a key part of the normalization procedure since CF
patients with early-stage lung disease typically do not have lung
disease present in the central lung regions. Thus, it is a logical
region to serve as a control in order to normalize the
measurements and thereby reduce subject-to-subject variation.
The primary outcome reported in the manuscript is the mean
normalized T1 value in the 3D upper lung region. Therefore, we
used equation 1 above to calculate a pixelwise map representing
the normalized T1 value at each spatial location. These maps were
then analyzed with an ROI analysis to calculate the mean nT1
value in the upper and lower lung regions for each subject. The
ROI analysis was performed over the central 4 imaging slices
while excluding imaging slices with heart tissue as well as chest
wall signal to avoid confounding in the T1 relaxation data.
Overall, the ROIs selected consisted of 103–104 pixels for each
subject.
Statistical Analysis
Mean absolute and normalized T1 relaxation times were plotted
as a function of FEV1% predicted and forced expiratory flow at
25–75% (FEF(25–75%)) for all CF patients and Pearson correla-
tion coefficients (r) were determined from a least squared error fit
to a linear model. The normalized T1 relaxation times and
spirometry results from the CF patients and healthy volunteers
were compared using two-tailed Student’s t-tests. The normalized
T1 values from the upper and lower regions were compared
among the two groups. Since this was an exploratory study of a
novel MRI technique, a priori power and sample size estimates
were not performed. A two-tailed P-value less than 0.05 was
considered statistically significant for all analyses. Analyses were
performed using Stata version 10.0 (StataCorp, College Station,
Texas).
Results
In this cross-sectional study we enrolled 10 CF patients and five
healthy volunteers. Subject characteristics are shown in Table 1.
CF patients ages ranged from 18–49 years and the mean [standard
deviation (SD)] FEV1 was 93% predicted (14.5) and ranged from
73% to 123% predicted. The average sweat chloride was 97 (22)
mmol per liter and 9/10 subjects had a sweat chloride greater than
60 mmol per liter. Five of the patients had a respiratory culture
positive for Pseudomonas aeruginosa; four of the five P. aeruginosa
isolates had a mucoid phenotype. The adult healthy volunteers
had no history of respiratory disease and their FEV1 values were
87%, 100%, 101%, 104%, and 118% predicted. Absolute T1
maps (left column) and the corresponding normalized T1 maps
(right column) from all five healthy control subjects are shown in
Figure 2. All of the healthy subjects exhibited relatively uniform
T1 relaxation times within each imaging slice as expected (i.e.
minimal regional differences in absolute and normalized T1
relaxation times). However, subject-to-subject variation is clearly
visible in the absolute T1 maps for the healthy subjects (left
column of Fig. 2). In contrast, the normalized T1 maps (right
column) exhibited minimal subject-to-subject variation as evi-
denced by an ROI analysis showing that the variation in the nT1
values in all regions was #2% of the mean.
Representative absolute T1 maps (left column) and normalized
T1 maps (right column) from 4 CF patients with a range of
pulmonary function (FEV1: 73%–100% predicted) are shown in
Figure 1. Manual ROI Selection. (a) A representative absolute T1
relaxation time map from a healthy volunteer. (b) The same image with
manual ROI’s overlaid. (UR =upper right lung region, UL =upper left
lung region, CR= central right lung region, CL = central left lung region,
LR = lower right lung region, LL = lower left lung region).
doi:10.1371/journal.pone.0073286.g001
Figure 2. Absolute and Normalized T1 Maps from Healthy
Volunteers. Absolute (left column) and normalized (right column) T1
maps from each of five healthy non-CF control subjects. The absolute
T1 maps exhibited visible subject-to-subject variation despite the
absence of known lung disease. The normalized T1 maps were
generated directly from the absolute T1 maps by dividing by the mean
central T1 relaxation time for each subject and resulted in reduced
subject-to-subject variation for the healthy control subjects. HV: healthy
volunteer.
doi:10.1371/journal.pone.0073286.g002
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Figure 3. In contrast to the healthy volunteers (HV, bottom row of
Fig. 3), CF patients exhibit visible spatial heterogeneity in the nT1
maps. Specifically, all CF patients (including the other 5 CF
patients not shown in Fig 3) exhibited regions of decreased nT1
values, particularly in the upper lung regions (black arrows in Fig. 3
right column). Importantly, these observed lung ‘‘lesions’’ are
much more conspicuous in the nT1 maps than in the absolute T1
maps demonstrating the importance of the normalization proce-
dure. Further, these lung ‘‘lesions’’ were observed in all CF
patients despite ‘‘normal’’ spirometry.
In addition to these qualitative results, mean nT1 values were
obtained in the upper and lower lung regions of each CF patient
and healthy volunteer. The mean nT1 value in the upper right
lung region (Fig. 4a), upper left lung region (Fig. 4b), lower right
lung region (Fig. 4c), and lower left lung region (Fig. 4d) were
plotted as a function of FEV1% predicted for all subjects and are
shown in Figure 4. Pearson correlation coefficients from a linear
regression of the mean nT1 values in each lung region were
calculated and are shown in each plot. Pearson correlation
coefficients from a linear regression of the mean nT1 values as a
function of FEF(25–75%) were also calculated. There was a
significant correlation between FEV1% predicted and nT1 values
in both the upper right and left lung regions (R2 = 0.45 and 0.61,
respectively; p,.05). There was also a significant correlation
between FEF(25–75%) in both the upper right and left lung
regions (R2 = 0.44 and 0.44, respectively; p,.05). Visual inspec-
tion of the plots reveals that the normalized T1 values in the upper
lung regions of the CF patients (black squares) are consistently
lower than the nT1 values for the healthy volunteers (open
diamonds). As expected in CF patients with early-stage lung
disease, there was no significant correlation between FEV1%
predicted or FEF(25–75%) and nT1 values in the lower lung
regions.
The primary outcome, a group analysis of the mean normalized
T1 values for the CF (n= 10) and healthy control (n = 5) groups, is
shown in Figure 5. The grouped data in figure 5 is also presented
in scatterplot form in Figure 4. The mean (SD) of the normalized
T1 value in the upper right lung of the CF subjects [.914 (.037)]
(black bars) was significantly lower than in the upper right lung
region of the healthy volunteers [.983 (.003)] (open bars). Thus, the
difference between the CF patients and the healthy controls in the
upper right lung region was .069 (95% confidence interval (CI)
.032 to .105); p = .001). Similarly, the mean nT1 value in the
upper left lung region [0.906 (.040)] was significantly lower than
the upper left lung region in the healthy subjects [0.984 (.011)]
(black bar). Thus, the difference between the CF patients and the
healthy controls in the upper left region was .078 (95% confidence
interval (CI) .038 to .118); p = .001). The mean nT1 differences
between the CF patients and healthy controls in both lower lung
regions (.031 and .037 for the lower right and lower left regions,
respectively) was as expected, less than observed in the upper lungs
regions. However, these differences were still statistically signifi-
cant due to the low variation in the nT1 methods (p,0.05).
Overall, it is important to note that these nT1 differences were
detected despite the CF patients having an average FEV1 of 93%
predicted resulting in no statistical difference in spirometry
between early-stage CF patients and healthy volunteers (p.0.05).
Discussion
In this preliminary cross-sectional study we evaluated if regional
lung function can be detected in adult CF patients with early-stage
lung disease using nT1-MRI. We found that normalized T1
relaxation times can reliably assess and differentiate lung
abnormalities in adult CF patients with early-stage lung disease
from healthy volunteers. There are many diagnostic tools that can
assess and differentiate later stages of CF lung disease. Therefore,
the most interesting finding from this study is that the normalized
T1 technique was able to detect early-stage CF lung disease
despite ‘‘normal’’ measurements of lung function using the current
gold standard, spirometry.
The pathophysiologic processes underlying the observed
decreases in lung nT1 values in CF patients shown here, and in
Table 1. Baseline Characteristics of the Study Cohort (n = 10).
Category* Result
Age, years 31 (10); [18–49]
Female, n (%) 4 (40)
FEV1% predicted 93 (15); [73–123]
Genotype, n (%)
DF508/DF508 6 (60)
DF508/Other 4 (40)
Sweat Chloride mmol per liter 97 (22); [46–124]
Respiratory Culture Results, n (%){
Pseudomonas aeruginosa 5 (50)
Methicillin-sensitive S. aureus 5 (50)
Methicillin-resistant S. aureus 2 (20)
*Continuous variables presented as mean (standard deviation); [range].
{Subjects could have more than one infection.
doi:10.1371/journal.pone.0073286.t001
Figure 3. Absolute and Normalized T1 Maps from CF Patients.
Representative absolute (left column) and normalized (right column) T1
relaxation time maps from four CF subjects (top four rows, FEV1:73%–
100% predicted) and one healthy volunteer (HV, bottom row). Regions
of decreased normalized T1 indicative of diseased lung are clearly
visible in the normalized T1 maps (black arrows). Note also the spatial
heterogeneity in the nT1 maps from the CF patients in comparison to
the uniform nT1 map of the healthy volunteer (HV).
doi:10.1371/journal.pone.0073286.g003
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absolute T1 relaxation times in previous oxygen-enhanced MRI
studies, is currently not established. In CF, dysfunction of the CF
transmembrane conductance regulator (CFTR) results in impaired
muco-ciliary clearance leading to an environment favorable for
infection and inflammation which ultimately destroys the lung[1].
It is hypothesized that early-stage CF lung disease stems from
obstruction of the small airways leading to ventilation defects and
hypoxic vasoconstriction[21]. Schraml and colleagues studied
Arterial Spin Labeling (ASL) MRI, a technique that is very specific
for blood flow, in CF patients. Their findings suggest that CF lung
disease detectable by MRI is associated with decreased regional
pulmonary blood flow[15]. As reduced blood flow would likely
result in reduced nT1 values, these ASL-MRI results suggest that
the reduced nT1-MRI values we observed in early-stage CF
patients (Figures 3–5) are related to reduced pulmonary blood
flow. Unfortunately, the ASL MRI techniques require extended
acquisition times, multiple image acquisitions, and a much more
complicated analysis in comparison to nT1-MRI making the ASL
somewhat impractical for routine clinical use. Further preclinical
and clinical MRI studies are needed to validate the reduced
pulmonary blood flow theory.
The normalized T1 relaxation time assessment builds upon
previously reported oxygen-enhanced MRI techniques and
provides several major advantages over current diagnostic tests
in our effort to develop a viable imaging biomarker for the
detection of early-stage lung disease in CF patients of all ages.
First, the rapid, normalized T1 assessment provides quantitative
MRI data in ,5 seconds/imaging slice. Patients require 8–10
slices to obtain these results, thus comprehensive 3D nT1-MRI
studies could easily be performed in less than 2–3 minutes. Second,
in contrast to other techniques such as infant pulmonary function
tests or lung clearance index which are not widely available, the
nT1 technique is widely generalizable as it can be performed on
practically any modern MRI scanner currently available at almost
all CF centers around the world. Third, MRI has no ionizing
radiation allowing this technique to be used safely to longitudinally
assess lung disease in even the youngest of patients (newborns to
infants), where the concern of ionizing radiation, especially repeat
studies, is heightened. Fourth, this technique does not require the
use of inhaled or intravenous contrast agents resulting in a safer
and simpler imaging procedure. The nT1 MRI technique
eliminates the need to provide supplemental oxygen, as in
previously published oxygen-enhanced MRI studies, and intrave-
nous or inhaled MRI contrast agents[10,13,22]. Removing the
need for oxygen respiration also eliminates tedious image co-
registration between the multiple T1 relaxation maps as these
images are typically acquired several minutes apart to allow for
oxygen/air wash-in. The lack of image co-registration for the nT1-
MRI is also a significant improvement over the ASL techniques
which require 20-50 image averages to quantify regional lung
blood flow. Fifth, our novel normalization process reduces inter-
subject variation by using the typically disease-free central lung
region as a control to normalize the MRI results in the CF patients
with early-stage CF lung disease. One advantage of the previously
discussed oxygen-enhanced MRI technique is facilitation of
effective subject to subject comparisons using multiple T1
measurements during respiration under room air and at various
oxygen concentrations to effectively ‘‘normalize’’ the results. Our
results shown here demonstrate that the normalization provided
by the nT1-MRI technique also minimizes subject-to-subject
variation as evidenced by the low variation in the results for the
healthy volunteers. Furthermore, the correlation with FEF(25–
75%) suggests detection of small airway disease[21]. FEF(25–75%)
is more variable than FEV1, making it less optimal as a clinical and
research tool[21]. Finally, this functional technique is capable of
obtaining regional information as opposed to spirometry which
Figure 4. Mean Regional Normalized T1 Values as a Function of FEV1% predicted. Mean regional normalized T1 (nT1) values as a function
of FEV1% predicted for all ten early-stage CF patients (black squares) and 5 healthy volunteers (open diamonds). (a) upper right lung region; (b) upper
left lung region; (c) lower right lung region; (d) lower left lung region. Linear regression lines and Pearson Correlation coefficients for the CF patients
(controls excluded) are also shown in each plot. The mean nT1 values in the upper left and right lung regions resulted in a significant linear
correlation (p,0.05) with FEV1% predicted despite the known variation in these spirometric results. As expected, the correlations for the mean
normalized T1 assessments in the lower lung regions were not significant (p.0.1). Note also the consistently lower mean nT1 values in the upper
right and left lung regions for the CF patients in comparison to healthy volunteers.
doi:10.1371/journal.pone.0073286.g004
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reflects global disease. Taken together, these results suggest that
regional, normalized T1 relaxometry may provide a sensitive and
clinically effective assessment of early-stage lung disease in CF.
This initial study of nT1 has several limitations. As this was a
preliminary study on the functional aspects of MRI in CF patients
with early-stage lung disease, structural studies were not
performed. Thus we did not correlate the abnormal regional
measurements in the upper lobes of the CF patients with structural
damage noted on either chest roentegrams or CT. Given that it is
known that CF lung disease begins in the upper lobes[16] and the
fact that contrast enhanced MRI studies have previously
correlated perfusion defects with structural changes[23], the
functional changes noted with the nT1-MRI technique most
likely represent pathophysiology consistent with early-stage CF
lung disease. Future studies will correlate our novel normalization
MRI technique with other imaging modalities. Another important
limitation of this study is the use of manual ROI selection to
perform the regional lung analysis and normalization. The
selection of the upper, lower, and central regions of the lungs
was primarily guided by the cystic fibrosis and radiologic expertise
of the coauthors. Despite this expertise, the ROI selection is
inherently subjective. However, each scan generated T1 maps for
at least 4 imaging slices. Therefore, each subject’s images were
used to generate mean T1 values for at least 24 ROIs (4 slices, 3
ROIs/lung, right and left lungs). In this way, the effects of a single
erroneous ROI selection on the overall mean T1 relaxation time is
somewhat diminished. Overall, the variation observed in the
results for the healthy volunteers was much lower for the nT1
technique in comparison to spirometry (#2% vs 11%). The
relatively low variation in the ROI analysis is also confirmed by
the consistency of the mean normalized T1 values in the left and
right lungs of all subjects as shown in Figures 4 and 5. The central
lung region was chosen for normalization of the T1 data primarily
because CF lung disease is known to be regional, first appearing in
the upper lung regions before the lower regions and the right side
before the left.[16,19] Therefore, the central regions of the lung as
shown in Figure 1 represent a region that is not generally expected
to contain diseased tissue until the disease has progressed to a
much later stage. As a result, for CF patients with early-stage lung
disease, the mean absolute T1 values in the central region could be
considered to be a ‘‘healthy’’ lung anatomic reference to assess the
pathophysiologic changes in the other regions of the lungs. In
addition, the central ROIs were predominantly selected because of
the large blood vessels easily observed in the absolute T1 maps.
Other anatomic regions in other tissues could have been chosen as
the reference (e.g. liver). However, normalizing to other tissues
would not be expected to correct for the subject-to-subject
variation in the lung vasculature and since CF is a systemic
disease there may be undetected disease in other tissues.
This technique could potentially benefit not only adults, but
newborns and young children with CF. As discussed, a significant
number of adolescent and adult CF patients have ‘‘normal’’ lung
function as measured by spirometry[3]. Unfortunately, these
patients are typically excluded from clinical trials as spirometry
lacks the sensitivity to detect changes in CF patients with early-
stage lung disease[24]. One primary goal of developing this
technique is to eventually apply it to newborns and young children
for both clinical and research purposes. It is thought that CF lung
disease begins in this young population prior to overt signs and
symptoms of lung disease[7,9,21,25]. Thus, tools are needed to
detect pre-symptomatic lung disease in these children. Given the
advantages of this technique elucidated earlier, it may be a safe
and effective diagnostic tool for newborns and young children.
This is an exciting time in cystic fibrosis as there are already
therapeutics available that treat the basic defect and several more
are in the pipeline[26]. It has already been shown that traditional
clinical endpoints (i.e. pulmonary exacerbations) may not be
sensitive enough to detect early, regional lung disease in newborns
and young children and thus new endpoints are needed[5]. Our
data, suggests that nT1-MRI is capable of detecting functional
changes in the lungs of adult CF patients with early-stage lung
disease, thus providing a strong impetus to determine if lung
lesions can be detected by nT1-MRI in infant and young children
with CF. Taken together, nT1-MRI may be a powerful tool
Figure 5. Comparison of mean regional nT1 values from the upper and lower lung regions for the CF patients and healthy
volunteers. A significant reduction in mean (SD) nT1 (**p = 0.001) was observed in the upper right (UR) [.914 (.037)] and upper left (UL) [0.906 (.040)]
lung regions (black bars) for the CF patients (n = 10) in comparison to the healthy control subjects (n = 5) UR [.983 (.003)] and UL [0.984 (.011)] lung
regions (open bars). The mean nT1 in the lower right (LR) and lower left (LL) lung regions was also significantly reduced for the CF patients in
comparison to healthy volunteers (*p,0.05). Importantly, these differences were observed despite normal spirometry in both groups.
doi:10.1371/journal.pone.0073286.g005
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enabling future strategies for the prevention and mitigation of CF
lung disease progression. This is vitally important as the reversal of
early-stage CF lung disease would result in longer and more
fulfilling lives for CF patients.
Conclusions
In conclusion, the results from this initial study suggest that the
normalized T1 MRI technique may provide a reliable and
sensitive marker for early-stage lung disease assessments in CF
patients. Specifically, the normalized T1 values in the upper lung
regions of early-stage CF patients were significantly decreased
relative to healthy controls despite ‘‘normal’’ spirometry. This
development suggests that normalized T1 relaxometry may
provide a safe and effective tool for assessing the extent of lung
disease in early-stage CF patients. Further studies are needed to
determine the exact mechanism of our findings and to extend the
utility of this technique to newborn and young children with CF.
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